[Drug induced gastro-intestinal tract lesions: A pathologist point of view].
Fiche publication
Date publication
mars 2023
Journal
Annales de pathologie
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BOULAGNON-ROMBI Camille
Tous les auteurs :
Boulagnon-Rombi C, Dufour C, Chatelain D
Lien Pubmed
Résumé
The number of drugs available to clinicians, especially targeted therapies, grows continuously. Some drugs are known to cause frequent digestive adverse effects, which may affect the gastro-intestinal tract in a diffuse or localized manner. Some treatments may leave relatively pathognomonic deposits, but histological lesions of iatrogenic origin are mostly non-specific. The diagnostic and etiological approach is often complex because of these non-specific aspects and also because (1) a single type of drug may cause different histological lesions, (2) different drugs may cause identical histological lesions, (3) the patient may receive different drugs, and (4) drug-induced lesions may mimic other pathological entities such as inflammatory bowel disease, celiac disease, or graft versus host disease. The diagnosis of iatrogenic gastrointestinal tract injury therefore requires close anatomic-clinical correlation. The iatrogenic origin can only be formally established if the symptomatology improves when the incriminating drug is stopped. This review aims to present the different histological patterns of gastrointestinal tract iatrogenic lesions, the potentially incriminate drugs, as well as the histological signs to look for in order to help the pathologist to distinguish an iatrogenic injury from another pathology of the gastrointestinal tract.
Mots clés
Acide mycophénolique, Adverse gastrointestinal tract drug effect, Checkpoint inhibitors, Drug induced injury, Effets indésirables gastro-intestinaux, Gastrointestinal tract, Inhibiteur des points de contrôle, Lésion induite par les médicaments, Mycophenolic acid, Tractus gastro-intestinal
Référence
Ann Pathol. 2023 03 1;: